-
After 5 years of production suspension, "comeback" to market. Zhang Yi, Chairman of Yisheng Biotechnology: Vaccine adjuvants are a bottleneck in the industry. Domestic approval still needs to be accelerated
On December 8th, Yisheng Biotechnology announced that the company's independently developed new immune anti-tumor drug YS-ON-001 has completed Phase I clinical research at Tianjin Cancer Hospital. Th ...